Evolent Health Company Profile (NYSE:EVH)

About Evolent Health (NYSE:EVH)

Evolent Health logoEvolent Health, Inc. is engaged in healthcare delivery and payment. The Company supports health systems and physician organizations in their migration toward value-based care and population health management. The Company provides an end-to-end, technology-enabled services platform for providers. The Company's platform, powered by its technology, processes and integrated services, enables providers to migrate their economic orientation from fee-for-service (FFS) reimbursement to payment models that reward value-based payment models. The Company's services include providing its customers, with a population management platform, integrated data and analytics capabilities, pharmacy benefit management (PBM) services and comprehensive health plan administration services. Its value-based operations are empowered and supported by Identifi. Identifi is the Company's technology platform that aggregates and analyzes data, manages care workflows and engages patients.

Industry, Sector and Symbol:
  • Sector: Computer and Technology
  • Industry: Medical Software & Technology Services
  • Sub-Industry: N/A
  • Symbol: NYSE:EVH
  • CUSIP: N/A
  • Web: www.evolenthealth.com
  • Market Cap: $1.11957 billion
  • Outstanding Shares: 65,822,000
Average Prices:
  • 50 Day Moving Avg: $17.13
  • 200 Day Moving Avg: $17.13
  • 52 Week Range: $14.50 - $27.50
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -850.00
  • P/E Growth: -1.33
Sales & Book Value:
  • Annual Revenue: $361.53 million
  • Price / Sales: 3.10
  • Book Value: $13.07 per share
  • Price / Book: 1.30
  • EBITDA: ($51,150,000.00)
  • Net Margins: -17.57%
  • Return on Equity: -6.44%
  • Return on Assets: -5.13%
  • Debt-to-Equity Ratio: 0.14%
  • Current Ratio: 1.89%
  • Quick Ratio: 1.89%
  • Average Volume: 1.55 million shs.
  • Beta: 1.33
  • Short Ratio: 24.8

Frequently Asked Questions for Evolent Health (NYSE:EVH)

What is Evolent Health's stock symbol?

Evolent Health trades on the New York Stock Exchange (NYSE) under the ticker symbol "EVH."

How were Evolent Health's earnings last quarter?

Evolent Health, Inc (NYSE:EVH) announced its quarterly earnings results on Monday, August, 7th. The company reported ($0.13) earnings per share for the quarter, meeting the consensus estimate of ($0.13). The company earned $107.30 million during the quarter, compared to analysts' expectations of $104.45 million. Evolent Health had a negative return on equity of 6.44% and a negative net margin of 17.57%. Evolent Health's quarterly revenue was up 89.9% on a year-over-year basis. During the same period last year, the business earned ($0.20) earnings per share. View Evolent Health's Earnings History.

Where is Evolent Health's stock going? Where will Evolent Health's stock price be in 2017?

13 brokers have issued 1 year price objectives for Evolent Health's stock. Their forecasts range from $23.00 to $32.00. On average, they anticipate Evolent Health's stock price to reach $28.45 in the next year. View Analyst Ratings for Evolent Health.

What are analysts saying about Evolent Health stock?

Here are some recent quotes from research analysts about Evolent Health stock:

  • 1. According to Zacks Investment Research, "Evolent Health, Inc. is involved in the healthcare delivery and payment markets. The company provides technology-enabled services platform for providers to transition their organization in value-based payment models. Evolent Health, Inc. is based in Arlington, Virginia. " (10/9/2017)
  • 2. Cantor Fitzgerald analysts commented, "4Q16 results were solid. Adjusted 4Q16 revenue of $90 million (+92.6% y/y) was above consensus expectations of $85.3 million. Revenue included contributions from Valence and Aldera. Revenue growth was driven by contributions from Valence and Aldera and by an increase in the number of lives on the company’s platform. The number of lives grew 181.5% y/y, reaching about 2.0 million lives in 4Q16. EVH also added another 600,000 lives to the platform in January 2017. Adjusted transformation revenue of $12.1 million increased 12% y/y. Transformation revenue can fluctuate quarter-to-quarter due to the timing of customer contracts and the scope of delivery. Adjusted platform and operation revenue of $77.9 million (+116.8%) benefited from an increased number of lives on the platform. Average PMPM was $12.87 in 4Q16 vs. $16.70." (3/1/2017)

Who are some of Evolent Health's key competitors?

Who are Evolent Health's key executives?

Evolent Health's management team includes the folowing people:

  • Seth Blackley, President
  • Frank John Williams, Chief Executive Officer, Director
  • Nicholas P. McGrane, Chief Financial Officer
  • Thomas Peterson III, Chief Operating Officer
  • Charles W. Pomeroy Jr., Chief Technology Officer
  • Lydia Stone, Principal Accounting Officer, Corporate Controller
  • Jonathan D. Weinberg, General Counsel
  • Dave Thornton, Chief Talent Officer
  • Steven J. Wigginton, Chief Development Officer
  • Bridget Duffy, Director

When did Evolent Health IPO?

(EVH) raised $150 million in an initial public offering (IPO) on Friday, June 5th 2015. The company issued 10,000,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan and Goldman Sachs acted as the underwriters for the IPO and Wells Fargo Securities, William Blair, SunTrust Robinson Humphrey and Leerink Partners were co-managers.

Who owns Evolent Health stock?

Evolent Health's stock is owned by many different of institutional and retail investors. Top institutional shareholders include JPMORGAN CHASE & COMPANY (10.00%) and Trellus Management Company LLC (0.03%). Company insiders that own Evolent Health stock include Board Co Advisory, Chad Pomeroy, Cheryl Scott, Frank J Williams, Jonathan Weinberg, Kenneth A Samet, Michael D'amato, Nicholas Mcgrane, Seth Blackley, Steve Wigginton, Thomas Peterson III, Tpg Growth Ii Advisors, Inc and Upmc. View Institutional Ownership Trends for Evolent Health.

Who bought Evolent Health stock? Who is buying Evolent Health stock?

Evolent Health's stock was bought by a variety of institutional investors in the last quarter, including Trellus Management Company LLC. View Insider Buying and Selling for Evolent Health.

How do I buy Evolent Health stock?

Shares of Evolent Health can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Evolent Health's stock price today?

One share of Evolent Health stock can currently be purchased for approximately $17.00.

MarketBeat Community Rating for Evolent Health (NYSE EVH)
Community Ranking:  3.6 out of 5 (star star star)
Outperform Votes:  242 (Vote Outperform)
Underperform Votes:  97 (Vote Underperform)
Total Votes:  339
MarketBeat's community ratings are surveys of what our community members think about Evolent Health and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Evolent Health (NYSE:EVH) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 12 Buy Ratings, 1 Strong Buy Rating
Consensus Rating:Buy (Score: 3.08)
Consensus Price Target: $28.45 (67.38% upside)
Consensus Price Target History for Evolent Health (NYSE:EVH)
Price Target History for Evolent Health (NYSE:EVH)
Analysts' Ratings History for Evolent Health (NYSE:EVH)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
10/6/2017Canaccord GenuityReiterated RatingBuy$32.00N/AView Rating Details
10/6/2017Cowen and CompanyReiterated RatingOutperform$33.00 -> $29.00N/AView Rating Details
9/26/2017Robert W. BairdReiterated RatingOutperform$35.00 -> $25.00HighView Rating Details
9/20/2017SunTrust Banks, Inc.Reiterated RatingBuy$30.00LowView Rating Details
9/19/2017KeyCorpInitiated CoverageOverweight -> Overweight$23.00LowView Rating Details
9/6/2017Jefferies Group LLCReiterated RatingBuy$28.00LowView Rating Details
8/18/2017Leerink SwannSet Price TargetBuy$32.00LowView Rating Details
8/18/2017J P Morgan Chase & CoReiterated RatingBuyLowView Rating Details
3/14/2017CIBCInitiated CoverageOutperform -> OutperformLowView Rating Details
3/13/2017Oppenheimer Holdings, Inc.Initiated CoverageOutperform$28.00LowView Rating Details
3/8/2017Goldman Sachs Group IncUpgradeBuy -> Conviction-Buy$30.00MediumView Rating Details
3/1/2017Cantor FitzgeraldReiterated RatingBuy$26.00N/AView Rating Details
1/13/2017Wells Fargo & CompanyUpgradeMarket Perform -> OutperformN/AView Rating Details
9/30/2016William BlairReiterated RatingOutperformN/AView Rating Details
8/5/2016FBR & CoBoost Price TargetOutperform$24.00 -> $26.00N/AView Rating Details
(Data available from 10/21/2015 forward)


Earnings History for Evolent Health (NYSE:EVH)
Earnings by Quarter for Evolent Health (NYSE:EVH)
Earnings History by Quarter for Evolent Health (NYSE EVH)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/7/2017Q2 2017($0.13)($0.13)$104.45 million$107.30 millionViewListenView Earnings Details
5/9/2017Q1 2017($0.15)($0.26)$104.38 million$106.80 millionViewListenView Earnings Details
2/28/2017Q416($0.20)($0.35)$84.98 million$88.00 millionViewListenView Earnings Details
11/9/2016Q316($0.13)($0.26)$58.35 million$60.20 millionViewListenView Earnings Details
8/4/2016Q216($0.16)($0.12)$51.96 million$56.50 millionViewN/AView Earnings Details
5/12/2016Q116($0.19)($0.16)$47.40 million$49.50 millionViewListenView Earnings Details
2/25/2016Q415($0.21)($0.05)$43.73 million$46.70 millionViewListenView Earnings Details
11/5/2015Q315($0.21)($0.16)$42.51 million$43.30 millionViewN/AView Earnings Details
8/6/2015Q215($0.37)($1.00)$157.50 million$36.50 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Evolent Health (NYSE:EVH)
2017 EPS Consensus Estimate: ($0.24)
2018 EPS Consensus Estimate: $0.03
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q2 20171($0.11)($0.11)($0.11)
Q3 20173($0.09)($0.07)($0.08)
Q4 20174($0.09)($0.03)($0.05)
Q1 20182($0.05)($0.04)($0.05)
Q2 20181$0.01$0.01$0.01
Q3 20181$0.02$0.02$0.02
Q4 20181$0.04$0.04$0.04
(Data provided by Zacks Investment Research)


Dividend History for Evolent Health (NYSE:EVH)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Evolent Health (NYSE:EVH)
Insider Ownership Percentage: 8.79%
Institutional Ownership Percentage: 82.51%
Insider Trades by Quarter for Evolent Health (NYSE:EVH)
Institutional Ownership by Quarter for Evolent Health (NYSE:EVH)
Insider Trades by Quarter for Evolent Health (NYSE:EVH)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/3/2017Frank J. WilliamsCEOSell16,300$23.73$386,799.00View SEC Filing  
8/1/2017Steve WiggintonCEOSell6,000$24.64$147,840.00View SEC Filing  
7/24/2017Thomas Peterson IIICOOSell40,540$26.00$1,054,040.00View SEC Filing  
7/10/2017Nicholas McgraneCFOSell1,667$25.42$42,375.14View SEC Filing  
7/6/2017Frank J. WilliamsCEOSell16,300$24.76$403,588.00View SEC Filing  
7/3/2017Steve WiggintonCEOSell6,000$25.07$150,420.00View SEC Filing  
6/28/2017Tpg Growth Ii Advisors, Inc.InsiderSell4,279,325$25.87$110,706,137.75View SEC Filing  
6/15/2017Seth BlackleyPresidentSell15,000$25.22$378,300.00View SEC Filing  
6/12/2017Nicholas McgraneCFOSell1,667$24.58$40,974.86View SEC Filing  
6/7/2017Nicholas McgraneCFOSell10,495$26.95$282,840.25View SEC Filing  
6/6/2017Kenneth A. SametDirectorSell4,000$25.75$103,000.00View SEC Filing  
6/6/2017Steve WiggintonCEOSell959$25.75$24,694.25View SEC Filing  
5/19/2017Cheryl ScottDirectorSell5,477$23.51$128,764.27View SEC Filing  
5/19/2017Frank J. WilliamsCEOSell114,865$24.30$2,791,219.50View SEC Filing  
5/19/2017Jonathan WeinbergGeneral CounselSell17,230$24.30$418,689.00View SEC Filing  
5/19/2017Nicholas McgraneCFOSell47,508$24.30$1,154,444.40View SEC Filing  
5/19/2017Thomas Peterson IIICOOSell57,433$24.30$1,395,621.90View SEC Filing  
5/19/2017Tpg Growth Ii Advisors, Inc.InsiderSell3,081,760$24.30$74,886,768.00View SEC Filing  
5/19/2017UpmcMajor ShareholderSell2,333,333$24.30$56,699,991.90View SEC Filing  
5/15/2017Seth BlackleyPresidentSell15,000$25.00$375,000.00View SEC Filing  
5/15/2017Thomas Peterson IIICOOSell83,108$24.99$2,076,868.92View SEC Filing  
5/10/2017Nicholas McgraneInsiderSell1,667$24.28$40,474.76View SEC Filing  
5/10/2017Thomas Peterson IIICOOSell18,604$25.00$465,100.00View SEC Filing  
5/4/2017Frank J WilliamsCEOSell16,300$23.55$383,865.00View SEC Filing  
5/3/2017Jonathan WeinbergGeneral CounselSell15,000$23.85$357,750.00View SEC Filing  
5/1/2017Steve WiggintonCEOSell6,000$23.10$138,600.00View SEC Filing  
5/1/2017UpmcMajor ShareholderSell403,644$19.53$7,883,167.32View SEC Filing  
4/19/2017Nicholas McgraneCFOSell1,667$22.52$37,540.84View SEC Filing  
4/17/2017Seth BlackleyPresidentSell15,000$21.48$322,200.00View SEC Filing  
4/6/2017Frank J WilliamsCEOSell16,300$22.03$359,089.00View SEC Filing  
4/3/2017Steve WiggintonCEOSell6,000$23.15$138,900.00View SEC Filing  
3/31/2017UpmcMajor ShareholderSell2,690,961$19.53$52,554,468.33View SEC Filing  
3/30/2017Seth BlackleyPresidentSell15,000$21.19$317,850.00View SEC Filing  
3/28/2017Board Co AdvisoryMajor ShareholderSell2,118,078$19.53$41,366,063.34View SEC Filing  
3/24/2017Nicholas McgraneCFOSell7,034$22.50$158,265.00View SEC Filing  
1/30/2017Seth BlackleyPresidentSell15,000$17.58$263,700.00View SEC Filing  
1/17/2017Seth BlackleyPresidentSell30,000$17.98$539,400.00View SEC Filing  
11/14/2016Michael D'amatoDirectorBuy10,000$17.18$171,800.00View SEC Filing  
9/22/2016Board Co AdvisoryMajor ShareholderSell317,712$22.50$7,148,520.00View SEC Filing  
9/14/2016Board Co AdvisoryMajor ShareholderSell1,936,529$22.50$43,571,902.50View SEC Filing  
9/14/2016Chad PomeroyInsiderSell55,180$21.54$1,188,577.20View SEC Filing  
9/14/2016Frank J WilliamsCEOSell251,481$21.54$5,416,900.74View SEC Filing  
9/14/2016Jonathan WeinbergGeneral CounselSell10,339$21.54$222,702.06View SEC Filing  
9/14/2016Nicholas McgraneCFOSell21,205$21.54$456,755.70View SEC Filing  
9/14/2016Seth BlackleyPresidentSell167,672$21.54$3,611,654.88View SEC Filing  
9/14/2016Thomas Peterson IIICOOSell72,827$21.54$1,568,693.58View SEC Filing  
6/10/2015Gary PieferInsiderBuy2,000$17.00$34,000.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Evolent Health (NYSE:EVH)
Latest Headlines for Evolent Health (NYSE:EVH)
investorplace.com logoLousy Quant Score Keeps Evolent Health (EVH) a Sell | InvestorPlace - Investorplace.com
investorplace.com - October 20 at 4:45 PM
investorplace.com logoLousy Quant Score Keeps Evolent Health (EVH) a Sell - Investorplace.com
www.investorplace.com - October 19 at 7:08 PM
finance.yahoo.com logoEvolent Health, Inc. to Release Third Quarter 2017 Operating Results and Host Conference Call on Thursday, November 2, 2017
finance.yahoo.com - October 19 at 7:08 PM
investorplace.com logoLousy Quant Score Keeps Evolent Health (EVH) a Sell
investorplace.com - October 19 at 2:38 PM
americanbankingnews.com logoEvolent Health, Inc (EVH) Receives Consensus Rating of "Buy" from Analysts
www.americanbankingnews.com - October 19 at 10:56 AM
americanbankingnews.com logoEvolent Health, Inc to Post Q1 2018 Earnings of ($0.04) Per Share, William Blair Forecasts (EVH)
www.americanbankingnews.com - October 18 at 11:50 AM
finance.yahoo.com logoETFs with exposure to Evolent Health, Inc. : October 17, 2017
finance.yahoo.com - October 17 at 7:11 PM
americanbankingnews.com logo Brokerages Anticipate Evolent Health, Inc (EVH) to Post -$0.09 EPS
www.americanbankingnews.com - October 16 at 12:30 PM
americanbankingnews.com logoComparing Evolent Health (EVH) and Its Competitors
www.americanbankingnews.com - October 13 at 2:20 PM
americanbankingnews.com logoEvolent Health, Inc (EVH) Upgraded by Zacks Investment Research to "Hold"
www.americanbankingnews.com - October 9 at 8:58 PM
americanbankingnews.com logoAnalyzing Evolent Health (EVH) and The Competition
www.americanbankingnews.com - October 8 at 10:34 PM
investorplace.com logoAnalytics Reaffirm Evolent Health (EVH) Sell Recommendation - Investorplace.com
investorplace.com - October 7 at 4:01 PM
americanbankingnews.com logoEvolent Health, Inc (EVH) Receives Buy Rating from Canaccord Genuity
www.americanbankingnews.com - October 7 at 7:54 AM
americanbankingnews.com logoCowen and Company Reaffirms Outperform Rating for Evolent Health, Inc (EVH)
www.americanbankingnews.com - October 6 at 3:38 PM
investorplace.com logoAnalytics Reaffirm Evolent Health (EVH) Sell Recommendation
investorplace.com - October 5 at 2:54 PM
prnewswire.com logoDemand for Telemedicine Virtual Care Technology Increases as a Result of Latest Disasters - PR Newswire (press release)
www.prnewswire.com - October 5 at 9:24 AM
americanbankingnews.com logoReviewing Evolent Health (EVH) and athenahealth (ATHN)
www.americanbankingnews.com - October 5 at 4:30 AM
americanbankingnews.com logoEvolent Health (EVH) and Omnicell (OMCL) Head-To-Head Contrast
www.americanbankingnews.com - October 4 at 9:12 AM
prnewswire.com logoDaily Technical Summary Reports on Healthcare Information Services Stocks -- Medical Transcription Billing, Cerner ... - PR Newswire (press release)
www.prnewswire.com - October 3 at 8:10 AM
americanbankingnews.com logoEvolent Health (EVH) versus Its Competitors Head-To-Head Survey
www.americanbankingnews.com - October 2 at 10:06 PM
americanbankingnews.com logoHead to Head Survey: Evolent Health (EVH) & Its Rivals
www.americanbankingnews.com - September 30 at 8:18 PM
prnewswire.com logoEvolent Health Announces Proposed Expansion of Relationships in ... - PR Newswire (press release)
www.prnewswire.com - September 29 at 2:22 PM
americanbankingnews.com logoLeerink Swann Research Analysts Lift Earnings Estimates for Evolent Health, Inc (EVH)
www.americanbankingnews.com - September 29 at 12:22 PM
americanbankingnews.com logo Analysts Expect Evolent Health, Inc (EVH) Will Announce Quarterly Sales of $104.54 Million
www.americanbankingnews.com - September 29 at 3:58 AM
americanbankingnews.com logoEvolent Health, Inc (EVH) Rating Reiterated by Robert W. Baird
www.americanbankingnews.com - September 26 at 4:24 PM
americanbankingnews.com logoEvolent Health, Inc (EVH) Given Consensus Recommendation of "Buy" by Analysts
www.americanbankingnews.com - September 24 at 10:44 AM
americanbankingnews.com logoSunTrust Banks Comments on Evolent Health, Inc's FY2017 Earnings (EVH)
www.americanbankingnews.com - September 22 at 7:22 AM
americanbankingnews.com logoSunTrust Banks Equities Analysts Cut Earnings Estimates for Evolent Health, Inc (EVH)
www.americanbankingnews.com - September 21 at 3:16 PM
americanbankingnews.com logoEvolent Health, Inc (EVH) Stock Rating Reaffirmed by SunTrust Banks, Inc.
www.americanbankingnews.com - September 20 at 5:10 PM
americanbankingnews.com logoKeyCorp Begins Coverage on Evolent Health, Inc (EVH)
www.americanbankingnews.com - September 19 at 9:34 PM
nasdaq.com logoOversold Conditions For Evolent Health (EVH)
www.nasdaq.com - September 15 at 6:59 PM
americanbankingnews.com logoEvolent Health, Inc (EVH) Given "Buy" Rating at Jefferies Group LLC
www.americanbankingnews.com - September 6 at 9:33 AM
americanbankingnews.com logoEvolent Health, Inc (EVH) Given Average Rating of "Buy" by Analysts
www.americanbankingnews.com - August 30 at 10:42 AM
americanbankingnews.com logoReviewing HealthEquity (HQY) & Evolent Health (EVH)
www.americanbankingnews.com - August 26 at 2:16 AM
americanbankingnews.com logo$104.65 Million in Sales Expected for Evolent Health, Inc (EVH) This Quarter
www.americanbankingnews.com - August 23 at 10:50 AM
americanbankingnews.com logoShort Interest in Evolent Health, Inc (EVH) Declines By 0.3%
www.americanbankingnews.com - August 22 at 11:34 PM
americanbankingnews.com logoAnalyzing Tabula Rasa HealthCare (TRHC) & Evolent Health (EVH)
www.americanbankingnews.com - August 22 at 12:18 AM
americanbankingnews.com logoNantHealth (NH) vs. Evolent Health (EVH) Head-To-Head Contrast
www.americanbankingnews.com - August 21 at 10:22 PM
americanbankingnews.com logo-$0.09 EPS Expected for Evolent Health, Inc (EVH) This Quarter
www.americanbankingnews.com - August 21 at 10:24 AM
americanbankingnews.com logoEvolent Health, Inc Forecasted to Post Q3 2017 Earnings of ($0.09) Per Share (EVH)
www.americanbankingnews.com - August 21 at 3:18 AM
americanbankingnews.com logoEvolent Health, Inc (EVH) Stock Rating Reaffirmed by J P Morgan Chase & Co
www.americanbankingnews.com - August 19 at 11:32 PM
americanbankingnews.com logoEvolent Health, Inc (EVH) PT Set at $32.00 by Leerink Swann
www.americanbankingnews.com - August 18 at 8:12 AM
americanbankingnews.com logoQ3 2017 Earnings Estimate for Evolent Health, Inc Issued By William Blair (EVH)
www.americanbankingnews.com - August 17 at 8:22 AM
finance.yahoo.com logoSee what the IHS Markit Score report has to say about Evolent Health Inc.
finance.yahoo.com - August 12 at 5:43 PM
americanbankingnews.com logoFY2017 EPS Estimates for Evolent Health, Inc (EVH) Reduced by Oppenheimer Holdings
www.americanbankingnews.com - August 11 at 12:02 PM
americanbankingnews.com logoQ3 2017 EPS Estimates for Evolent Health, Inc (NYSE:EVH) Decreased by Analyst
www.americanbankingnews.com - August 11 at 9:34 AM
finance.yahoo.com logoEvolent Health, Inc. :EVH-US: Earnings Analysis: Q2, 2017 By the Numbers : August 10, 2017
finance.yahoo.com - August 10 at 7:45 PM
finance.yahoo.com logoEdited Transcript of EVH earnings conference call or presentation 7-Aug-17 9:00pm GMT
finance.yahoo.com - August 9 at 4:23 AM
finance.yahoo.com logoEvolent Health, Inc. Announces Pricing of Public Offering of Class A Common Stock
finance.yahoo.com - August 8 at 11:19 PM
seekingalpha.com logoEvolent Health's (EVH) CEO Frank Williams on Q2 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - August 8 at 6:15 PM



Evolent Health (EVH) Chart for Saturday, October, 21, 2017

This page was last updated on 10/21/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.